Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

出版年份 2016 全文链接

标题

作者

关键词

出版物

Volume 27, Issue suppl_6, Pages -

出版商

Oxford University Press (OUP)

发表日期

2017-02-04

DOI

10.1093/annonc/mdw363.25

Discuss science. Find collaborators. Network.

Join a conversation

Explore over 38,000 international journals covering a vast array of academic fields.